Suppr超能文献

二肽基肽酶IV抑制剂NVP-DPP728可改善老年大鼠的早期胰岛素反应和葡萄糖耐量,但对缺乏该酶活性的老年费希尔344大鼠无效。

Dipeptidyl peptidase IV inhibitor NVP-DPP728 ameliorates early insulin response and glucose tolerance in aged rats but not in aged Fischer 344 rats lacking its enzyme activity.

作者信息

Mitani Hironobu, Takimoto Misato, Kimura Masaaki

机构信息

Research Division, Tsukuba Research Institute, Novartis Pharma K.K., Japan.

出版信息

Jpn J Pharmacol. 2002 Apr;88(4):451-8. doi: 10.1254/jjp.88.451.

Abstract

The aim of this study was to investigate the effects of aging on glucose metabolism after oral glucose challenge in aged dipeptidyl peptidase IV (DPP-IV) positive (+) Fischer 344 (F344), DPP-IV deficient (-) F344 and DPP-IV(+) Wistar rats and to determine the effect of a DPP-IV inhibitor NVP-DPP728 (1-[2-[(5-cyanopyridin-2-yl)amino]ethylamino]acetyl-2-cyano-(S)-pyrrolidine monohydrochloride salt) on glucose tolerance in aged rats. Aging caused a decrease in early insulin response after an oral glucose challenge in aged Wistar or DPP-IV(+) F344 rats, but not in aged DPP-IV(-) F344 rats, compared with young control groups. Glucose tolerance after an oral glucose challenge in aged DPP-IV(-) F344 rats was better than in aged DPP-IV(+) F344 and Wistar rats associated with the preservation of the early insulin response. NVP-DPP728 improved the glucose tolerance after an oral glucose challenge by potentiating the early insulin response throughout the inhibition of plasma DPP-IV activity in aged DPP-IV(+) Wistar and F344 rats. In contrast, NVP-DPP728 did not affect the glucose tolerance after an oral glucose challenge in aged DPP-IV(-) F344 rats. These results indicate that treatment with NVP-DPP728 ameliorated glucose tolerance in aged rats by the direct inhibition of plasma DPP-IV activity and presumably the subsequent increase in endogenous incretin action.

摘要

本研究旨在探讨衰老对老年二肽基肽酶IV(DPP-IV)阳性(+)的Fischer 344(F344)大鼠、DPP-IV缺陷(-)的F344大鼠以及DPP-IV(+)的Wistar大鼠口服葡萄糖激发后葡萄糖代谢的影响,并确定DPP-IV抑制剂NVP-DPP728(1-[2-[(5-氰基吡啶-2-基)氨基]乙基氨基]乙酰基-2-氰基-(S)-吡咯烷盐酸盐)对老年大鼠葡萄糖耐量的影响。与年轻对照组相比,衰老导致老年Wistar或DPP-IV(+)F344大鼠口服葡萄糖激发后早期胰岛素反应降低,但老年DPP-IV(-)F344大鼠未出现这种情况。老年DPP-IV(-)F344大鼠口服葡萄糖激发后的葡萄糖耐量优于老年DPP-IV(+)F344大鼠和Wistar大鼠,这与早期胰岛素反应的保留有关。NVP-DPP728通过增强老年DPP-IV(+)Wistar和F344大鼠血浆DPP-IV活性的抑制作用来增强早期胰岛素反应,从而改善口服葡萄糖激发后的葡萄糖耐量。相比之下,NVP-DPP728对老年DPP-IV(-)F344大鼠口服葡萄糖激发后的葡萄糖耐量没有影响。这些结果表明,NVP-DPP728治疗通过直接抑制血浆DPP-IV活性以及可能随后增加内源性肠促胰岛素作用,改善了老年大鼠的葡萄糖耐量。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验